Haemonetics Consolidates Segments for Reporting Clarity

By Hao Liu • Friday, June 05 10:56 • Permanent Link

Haemonetics is changing its reporting structure from three segments to two, a move that will reshape how investors compare the company’s revenue trends beginning with fiscal 2027.

The company said it will combine its plasma and blood center businesses into a single reportable segment called apheresis. Its hospital segment will be renamed medsurg. Under the new structure, Haemonetics will report:

Apheresis: includes plasma and other, plus blood center-related revenue
Medsurg: includes blood management technologies and interventional technologies

Haemonetics said the new segment structure will take effect with first-quarter fiscal 2027, which began March 29, 2026.

To make the new structure comparable with prior periods, the company has recast quarterly historical revenue for fiscal 2024, 2025, and 2026. It also recast its previously issued fiscal 2027 revenue guidance to match the new segment layout.

The company said the updated presentation is not a reaffirmation or update of fiscal 2027 guidance. Any changes will come with its first-quarter fiscal 2027 earnings call.

The practical result is that investors will now track two operating lines instead of three, with the company’s plasma and blood center revenue folded together into a single apheresis figure. As a result of these announcements, the company's shares have moved 1.53% on the market, and are now trading at a price of $70.9225. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.